Source comparison
Wolverine Stack ACL Injury Recovery: Research vs Commercial Applications
BPC-157 Dosing 250–500 mcg twice daily, 6–8 weeks 250 mcg once daily, inconsistent duration Twice-daily dosing maintains therapeutic levels; once-daily underdoses the angiogenic window TB-500 Loading 5 mg twice weekly × 2 weeks, then 2 mg weekly 2 mg once week
This comparison does not assign a generated winner or score.
- BPC-157 Dosing
- 250–500 mcg twice daily, 6–8 weeks
- 250 mcg once daily, inconsistent duration
- Twice-daily dosing maintains therapeutic levels; once-daily underdoses the angiogenic window
- TB-500 Loading
- 5 mg twice weekly × 2 weeks, then 2 mg weekly
- 2 mg once weekly from start
- Front-loading saturates receptors faster during acute inflammation; skipping this phase delays peak effect by 10–14 days
- GH Secretagogue Selection
- GHRP-2 or CJC-1295 (pulsatile vs sustained release)
- MK-677 (convenience over efficacy)
- MK-677 elevates IGF-1 but doesn't replicate physiological GH pulses; GHRP-2 produces sharper anabolic signaling at the cost of injection frequency
- Injection Site Proximity
- Within 2–5 cm of injury site for BPC-157
- Abdominal subcutaneous (generic)
- Local administration increases tissue concentration 3–5× vs systemic; abdominal injections reduce peptide efficacy for localized injuries
- Monitoring Metrics
- Ultrasound graft echogenicity, isokinetic strength testing
- Subjective pain and ROM
- Without imaging or strength data, you're guessing whether collagen remodeling is progressing or stalling
- Bottom Line
- Research protocols prioritize mechanism-targeted dosing and timing; commercial use often defaults to convenience, which compromises efficacy